A Phase 2 Study of Venetoclax With Safety Lead-In for Treatment of Relapsed/Refractory Mature T-Cell Lymphomas
Phase of Trial: Phase II
Latest Information Update: 28 Sep 2018
At a glance
- Drugs Venetoclax (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 21 Sep 2018 Planned End Date changed from 1 Oct 2020 to 1 Sep 2020.
- 21 Sep 2018 Planned primary completion date changed from 1 Oct 2020 to 1 Sep 2020.
- 22 Aug 2018 Status changed from not yet recruiting to recruiting.